ICU Medical Inc: Form 10-Q for the period ended Jun 30, 2016
Filed with the SEC on Aug 9, 2016 and accepted by EDGAR at Aug 9, 2016, 12:38 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2016-06-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2016-04-01 to 2016-06-30 | $96.7m | us-gaap:Revenues |
| Revenue | 6 months2016-01-01 to 2016-06-30 | $186.6m | us-gaap:Revenues |
| Cost of revenue | 3 months2016-04-01 to 2016-06-30 | $46.6m | us-gaap:CostOfGoodsSold |
| Cost of revenue | 6 months2016-01-01 to 2016-06-30 | $87.2m | us-gaap:CostOfGoodsSold |
| Gross profit | 3 months2016-04-01 to 2016-06-30 | $50.1m | us-gaap:GrossProfit |
| Gross profit | 6 months2016-01-01 to 2016-06-30 | $99.4m | us-gaap:GrossProfit |
| Research and development | 3 months2016-04-01 to 2016-06-30 | $3.3m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 6 months2016-01-01 to 2016-06-30 | $6.7m | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 3 months2016-04-01 to 2016-06-30 | $22.5m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 6 months2016-01-01 to 2016-06-30 | $44.5m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months2016-04-01 to 2016-06-30 | $22.8m | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months2016-01-01 to 2016-06-30 | $46.7m | us-gaap:OperatingIncomeLoss |
| Income tax | 3 months2016-04-01 to 2016-06-30 | $7.4m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 6 months2016-01-01 to 2016-06-30 | $13.3m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 6 months2016-01-01 to 2016-06-30 | $34.8m | us-gaap:ProfitLoss |
| Diluted EPS | 3 months2016-04-01 to 2016-06-30 | $0.98 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 6 months2016-01-01 to 2016-06-30 | $2.05 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2016-04-01 to 2016-06-30 | $1.03 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 6 months2016-01-01 to 2016-06-30 | $2.16 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2016-04-01 to 2016-06-30 | 17,000,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 6 months2016-01-01 to 2016-06-30 | 16,964,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 6 months2016-01-01 to 2016-06-30 | $41.8m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 6 months2016-01-01 to 2016-06-30 | $9.1m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Share repurchases | 6 months2016-01-01 to 2016-06-30 | $16.9m | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | At period end2016-06-30 | $372.9m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2016-06-30 | $535.4m | us-gaap:AssetsCurrent |
| Total assets | At period end2016-06-30 | $663.4m | us-gaap:Assets |
| Current liabilities | At period end2016-06-30 | $40.6m | us-gaap:LiabilitiesCurrent |
| Shareholders' equity | At period end2016-06-30 | $616.2m | us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest |
Source: SEC EDGAR, the filing index for accession 0000883984-16-000077. Last ingested by Listed: Nov 14, 2026, 20:54 ET. Listed shows no prices and gives no investment advice.